Cheng Long Huang

Title: Innovations of Cheng Long Huang in Antitumor Research

Introduction

Cheng Long Huang is a notable inventor based in Kyoto, Japan. He has made significant contributions to the field of antitumor research, particularly through his innovative approaches to RNA interference (RNAi) technology. With a total of 2 patents, his work focuses on developing effective methods for delivering therapeutic agents to combat cancer.

Latest Patents

One of Cheng Long Huang's latest patents is titled "Liposome containing shRNA molecule targeting a thymidylate synthase and use thereof." This invention provides a method for delivering short hairpin RNA (shRNA) targeting thymidylate synthase (TS) in vivo. The method includes an antitumor agent that comprises shRNA capable of inhibiting the expression of TS through RNAi action. The shRNA is bound to the surface of a PEG-modified cationic liposome, featuring an overhang of at least two nucleotides at the 3' end.

Another significant patent is "RNAi molecule targeting thymidylate synthase and application thereof." This invention introduces a novel RNAi molecule that can significantly enhance the antitumor effects of a 5-FU antitumor agent. The RNAi molecule comprises a specific nucleotide sequence, as shown in SEQ ID NO: 2. Additionally, the invention provides an antitumor agent that includes this RNAi molecule along with a 5-FU antitumor agent.

Career Highlights

Cheng Long Huang is currently associated with Delta-Fly Pharma, Inc., where he continues to advance his research in the field of cancer therapeutics. His work is characterized by a strong focus on innovative solutions that leverage RNAi technology to improve treatment outcomes for patients.

Collaborations

Cheng Long Huang collaborates with esteemed colleagues, including Hiromi Wada and Tatsuhiro Ishida. Their combined expertise contributes to the development of groundbreaking therapies in the fight against cancer.

Conclusion

Cheng Long Huang's contributions to antitumor research through his innovative patents highlight the potential of RNAi technology in cancer treatment. His work at Delta-Fly Pharma, Inc. continues to pave the way for advancements in therapeutic strategies.